Back
Speaker illustration

Doctor Oriol Iborra Egea

Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona (Spain)

Member of:

Molecular Biologist (BSc), Geneticist (MSc) and PhD in cardiovascular research. Boardmember at the Catalan Society of Biology. Dr Iborra-Egea has participated in several, large proteomic/transcriptomic studies in cardiovascular research: from novel biomarker discovery in cardiogenic shock to precision medicine and miRNAs analysis and their prognostic/clinical value, as well as gained expertise in using AI techniques to explore novel drugs' mechanisms of action. With a strong background on iPSC technology and in clonal hematopoiesis studies in bone marrow, Dr. Iborra-Egea works as a post-doctoral researcher at the ICREC program (Barcelona). Dr. Iborra-Egea is also a business-savvy enterpreneur with technology transfer experience in the biotech field. v Cum Laude PhD (Novel approaches towards precision medicine in chronic and acute heart failure) v Young Scientist Award at the BCS 2017 in Sweden and Finland v Awarded the State Program for the Promotion of Talent 2015 (Spain)

Presentations

It is due to NHE blockade at the cardiomyocyte

Event: HFA Winter Research Meeting on Translational Heart Failure 2023

Topic: Basic Science

Session: Understanding the cardiovascular effects of SGLT2 inhibitors

Access
Like
Thumbnail

Ketone bodies for the failing heart.

Event: Heart Failure 2022

Topic: Signal Transduction, Mechanotransduction

Session: What fuels the heart matters

Access
Like
Thumbnail

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Ischaemia, Infarction, Cardioprotection

Session: Poster Session 1

Access
Like
Thumbnail

Mechanisms of cardiac protection by pirfenidone in the post-myocardial infarction setting

Event: ESC Congress 2021 - The Digital Experience

Topic: Pathophysiology and Mechanisms

Session: Coronary Artery Disease (Chronic)/Chronic Coronary Syndromes ePosters

Access
Like
Thumbnail

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Event: ESC Congress 2021 - The Digital Experience

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Congress committee e-posters choice in heart failure

Access
Like
Thumbnail

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Event: Heart Failure 2021

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 1

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources